Ira M Longini,
Professor
Teaching Profile
Courses Taught
2013,2016-2018,2018-2023,2020-2024,2023-2024
PHC6937 Special Topics in Public Health
2012-2018,2023-2024
PHC7979 Advanced Research
2015-2017,2022
PHC7980 Research for Doctoral Dissertation
2014
PHC7910 International Field Epidemiology
2014
STA7179 Survival Analysis
2023
PHC6905 Independent Study
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-2780-9382
Publications
2023
Covariate-constrained randomization with cluster selection and substitution
Clinical Trials.
20(3):284-292
[DOI] 10.1177/17407745231160556.
2023
Quantifying the value of viral genomics when inferring who infected whom in the 2014-16 Ebola virus outbreak in Guinea.
Virus evolution.
9(1)
[DOI] 10.1093/ve/vead007.
[PMID] 36926449.
2022
A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats
Clinical Trials.
19(6):647-654
[DOI] 10.1177/17407745221110880.
[PMID] 35866633.
2022
An introduction to the Marburg virus vaccine consortium, MARVAC.
PLoS pathogens.
18(10)
[DOI] 10.1371/journal.ppat.1010805.
[PMID] 36227853.
2022
Estimating the impact of COVID-19 vaccine allocation inequities: a modeling study.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2022.11.18.22282514.
[PMID] 36415459.
2022
Evolutionary consequences of delaying intervention for monkeypox.
Lancet (London, England).
400(10359):1191-1193
[DOI] 10.1016/S0140-6736(22)01789-5.
[PMID] 36152668.
2022
Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2022.01.09.22268984.
[PMID] 35043125.
2022
Household Secondary Attack Rates of SARS-CoV-2 by Variant and Vaccination Status: An Updated Systematic Review and Meta-analysis.
JAMA network open.
5(4)
[DOI] 10.1001/jamanetworkopen.2022.9317.
[PMID] 35482308.
2022
Quantifying the importance and location of SARS-CoV-2 transmission events in large metropolitan areas.
Proceedings of the National Academy of Sciences of the United States of America.
119(26)
[DOI] 10.1073/pnas.2112182119.
[PMID] 35696558.
2022
The ring vaccination trial design for the estimation of vaccine efficacy and effectiveness during infectious disease outbreaks.
Clinical trials (London, England).
19(4):402-406
[DOI] 10.1177/17407745211073594.
[PMID] 35057647.
2021
Considerations in boosting COVID-19 vaccine immune responses.
Lancet (London, England).
398(10308):1377-1380
[DOI] 10.1016/S0140-6736(21)02046-8.
[PMID] 34534516.
2021
COVID-19 vaccine trials: The potential for “hybrid” analyses.
Clinical trials (London, England).
18(4):391-397
[DOI] 10.1177/17407745211018613.
[PMID] 34041932.
2021
COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
Clinical trials (London, England).
18(3):335-342
[DOI] 10.1177/1740774520988244.
[PMID] 33535811.
2021
Cryptic transmission of SARS-CoV-2 and the first COVID-19 wave.
Nature.
600(7887):127-132
[DOI] 10.1038/s41586-021-04130-w.
[PMID] 34695837.
2021
Factors Associated With Household Transmission of SARS-CoV-2: An Updated Systematic Review and Meta-analysis.
JAMA network open.
4(8)
[DOI] 10.1001/jamanetworkopen.2021.22240.
[PMID] 34448865.
2021
Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study.
The Lancet. Infectious diseases.
21(5):617-628
[DOI] 10.1016/S1473-3099(20)30981-6.
[PMID] 33476567.
2021
Inferring high-resolution human mixing patterns for disease modeling.
Nature communications.
12(1)
[DOI] 10.1038/s41467-020-20544-y.
[PMID] 33436609.
2021
Placebo-Controlled Trials of Covid-19 Vaccines – Why We Still Need Them.
The New England journal of medicine.
384(2)
[DOI] 10.1056/NEJMp2033538.
[PMID] 33264543.
2021
SARS-CoV-2 Variants and Vaccines.
The New England journal of medicine.
385(2):179-186
[DOI] 10.1056/NEJMsr2105280.
[PMID] 34161052.
2021
Using simulated infectious disease outbreaks to inform site selection and sample size for individually randomized vaccine trials during an ongoing epidemic.
Clinical trials (London, England).
18(5):630-638
[DOI] 10.1177/17407745211028898.
[PMID] 34218667.
2020
Achieving coordinated national immunity and cholera elimination in Haiti through vaccination: a modelling study.
The Lancet. Global health.
8(8):e1081-e1089
[DOI] 10.1016/S2214-109X(20)30310-7.
[PMID] 32710864.
2020
COVID-19 vaccine trials should seek worthwhile efficacy.
Lancet (London, England).
396(10253):741-743
[DOI] 10.1016/S0140-6736(20)31821-3.
[PMID] 32861315.
2020
Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks.
The New England journal of medicine.
382(14):1366-1369
[DOI] 10.1056/NEJMsb1905390.
[PMID] 32242365.
2020
Designing a Study of Correlates of Risk for Ebola Vaccination.
American journal of epidemiology.
189(8):747-754
[DOI] 10.1093/aje/kwaa001.
[PMID] 31971229.
2020
Designing effective control of dengue with combined interventions.
Proceedings of the National Academy of Sciences of the United States of America.
117(6):3319-3325
[DOI] 10.1073/pnas.1903496117.
[PMID] 31974303.
2020
Ensemble forecast modeling for the design of COVID-19 vaccine efficacy trials.
Vaccine.
38(46):7213-7216
[DOI] 10.1016/j.vaccine.2020.09.031.
[PMID] 33012602.
2020
Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study.
The Lancet. Infectious diseases.
20(7):793-802
[DOI] 10.1016/S1473-3099(20)30230-9.
[PMID] 32247326.
2020
Evolving epidemiology of novel coronavirus diseases 2019 and possible interruption of local transmission outside Hubei Province in China: a descriptive and modeling study.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2020.02.21.20026328.
[PMID] 32511424.
2020
Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study.
The Lancet. Infectious diseases.
20(10):1141-1150
[DOI] 10.1016/S1473-3099(20)30471-0.
[PMID] 32562601.
2020
Household Secondary Attack Rate of COVID-19 and Associated Determinants.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2020.04.11.20056010.
[PMID] 32511590.
2020
Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis.
JAMA network open.
3(12)
[DOI] 10.1001/jamanetworkopen.2020.31756.
[PMID] 33315116.
2020
Modelling the impact of testing, contact tracing and household quarantine on second waves of COVID-19.
Nature human behaviour.
4(9):964-971
[DOI] 10.1038/s41562-020-0931-9.
[PMID] 32759985.
2020
Temporal Confounding in the Test-Negative Design.
American journal of epidemiology.
189(11):1402-1407
[DOI] 10.1093/aje/kwaa084.
[PMID] 32415834.
2020
The effect of travel restrictions on the spread of the 2019 novel coronavirus (2019-nCoV) outbreak.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2020.02.09.20021261.
[PMID] 32511423.
2020
The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak
Science.
368(6489):395-400
[DOI] 10.1126/science.aba9757.
[PMID] 32144116.
2020
The TIRS trial: protocol for a cluster randomized controlled trial assessing the efficacy of preventive targeted indoor residual spraying to reduce Aedes-borne viral illnesses in Merida, Mexico.
Trials.
21(1)
[DOI] 10.1186/s13063-020-04780-7.
[PMID] 33032661.
2019
An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool.
Vaccine.
37(31):4376-4381
[DOI] 10.1016/j.vaccine.2019.06.019.
[PMID] 31242963.
2019
Design of vaccine efficacy trials during public health emergencies
Science Translational Medicine.
11(499)
[DOI] 10.1126/scitranslmed.aat0360.
[PMID] 31270270.
2019
Determinants of Transmission Risk During the Late Stage of the West African Ebola Epidemic.
American journal of epidemiology.
188(7):1319-1327
[DOI] 10.1093/aje/kwz090.
[PMID] 30941398.
2019
Effects of infection history on dengue virus infection and pathogenicity.
Nature communications.
10(1)
[DOI] 10.1038/s41467-019-09193-y.
[PMID] 30886145.
2019
Genomic epidemiology supports multiple introductions and cryptic transmission of Zika virus in Colombia.
BMC infectious diseases.
19(1)
[DOI] 10.1186/s12879-019-4566-2.
[PMID] 31718580.
2018
Biofilms Comprise a Component of the Annual Cycle of Vibrio cholerae in the Bay of Bengal Estuary.
mBio.
9(2)
[DOI] 10.1128/mBio.00483-18.
[PMID] 29666284.
2018
Dengue seroprevalence in a cohort of schoolchildren and their siblings in Yucatan, Mexico (2015-2016).
PLoS neglected tropical diseases.
12(11)
[DOI] 10.1371/journal.pntd.0006748.
[PMID] 30462654.
2018
Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
66(2):178-184
[DOI] 10.1093/cid/cix766.
[PMID] 29020332.
2018
DESIGN OF VACCINE TRIALS DURING OUTBREAKS WITH AND WITHOUT A DELAYED VACCINATION COMPARATOR.
The annals of applied statistics.
12(1):330-347
[DOI] 10.1214/17-AOAS1095.
[PMID] 29606991.
2018
Epidemiology of dengue and other arboviruses in a cohort of school children and their families in Yucatan, Mexico: Baseline and first year follow-up.
PLoS neglected tropical diseases.
12(11)
[DOI] 10.1371/journal.pntd.0006847.
[PMID] 30462635.
2018
Forecasting the effectiveness of indoor residual spraying for reducing dengue burden.
PLoS neglected tropical diseases.
12(6)
[DOI] 10.1371/journal.pntd.0006570.
[PMID] 29939983.
2018
Intermediate levels of vaccination coverage may minimize seasonal influenza outbreaks.
PloS one.
13(6)
[DOI] 10.1371/journal.pone.0199674.
[PMID] 29944709.
2018
Quantifying the risk of local Zika virus transmission in the contiguous US during the 2015-2016 ZIKV epidemic.
BMC medicine.
16(1)
[DOI] 10.1186/s12916-018-1185-5.
[PMID] 30336778.
2018
Questionable efficacy of the rVSV-ZEBOV Ebola vaccine – Authors’ reply.
Lancet (London, England).
391(10125):1021-1022
[DOI] 10.1016/S0140-6736(18)30559-2.
[PMID] 29565012.
2018
Reply to Aguiar and Stollenwerk.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
66(4)
[DOI] 10.1093/cid/cix883.
[PMID] 29088434.
2018
Seroprevalence of Dengue Antibodies in Three Urban Settings in Yucatan, Mexico.
The American journal of tropical medicine and hygiene.
98(4):1202-1208
[DOI] 10.4269/ajtmh.17-0382.
[PMID] 29460714.
2018
Spatio-temporal coherence of dengue, chikungunya and Zika outbreaks in Merida, Mexico.
PLoS neglected tropical diseases.
12(3)
[DOI] 10.1371/journal.pntd.0006298.
[PMID] 29543910.
2018
Transmissibility of Norovirus in Urban Versus Rural Households in a Large Community Outbreak in China.
Epidemiology (Cambridge, Mass.).
29(5):675-683
[DOI] 10.1097/EDE.0000000000000855.
[PMID] 29847497.
2017
Controlling cholera in the Ouest Department of Haiti using oral vaccines.
PLoS neglected tropical diseases.
11(4)
[DOI] 10.1371/journal.pntd.0005482.
[PMID] 28410382.
2017
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).
Lancet (London, England).
389(10068):505-518
[DOI] 10.1016/S0140-6736(16)32621-6.
[PMID] 28017403.
2017
Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness.
Vaccine.
35(42):5535-5542
[DOI] 10.1016/j.vaccine.2017.08.066.
[PMID] 28893477.
2017
Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report.
The Lancet. Infectious diseases.
17(12):1276-1284
[DOI] 10.1016/S1473-3099(17)30541-8.
[PMID] 29033032.
2017
Simulations for designing and interpreting intervention trials in infectious diseases.
BMC medicine.
15(1)
[DOI] 10.1186/s12916-017-0985-3.
[PMID] 29287587.
2017
Spread of Zika virus in the Americas.
Proceedings of the National Academy of Sciences of the United States of America.
114(22):E4334-E4343
[DOI] 10.1073/pnas.1620161114.
[PMID] 28442561.
2017
The public health value of vaccines beyond efficacy: methods, measures and outcomes.
BMC medicine.
15(1)
[DOI] 10.1186/s12916-017-0911-8.
[PMID] 28743299.
2016
Changes in the primary outcome in Ebola vaccine trial–Authors’ reply.
Lancet (London, England).
387(10027):1509-1510
[DOI] 10.1016/S0140-6736(16)00686-3.
[PMID] 27115974.
2016
Containing Ebola at the Source with Ring Vaccination.
PLoS neglected tropical diseases.
10(11)
[DOI] 10.1371/journal.pntd.0005093.
[PMID] 27806049.
2016
Correction: Cholera Transmission in Ouest Department of Haiti: Dynamic Modeling and the Future of the Epidemic.
PLoS neglected tropical diseases.
10(1)
[DOI] 10.1371/journal.pntd.0004377.
[PMID] 26736014.
2016
Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies.
Vaccine.
34(33):3796-802
[DOI] 10.1016/j.vaccine.2016.05.067.
[PMID] 27268778.
2016
Molecular Infectious Disease Epidemiology: Survival Analysis and Algorithms Linking Phylogenies to Transmission Trees.
PLoS computational biology.
12(4)
[DOI] 10.1371/journal.pcbi.1004869.
[PMID] 27070316.
2016
PREDICTIVE MODELING OF CHOLERA OUTBREAKS IN BANGLADESH.
The annals of applied statistics.
10(2):575-595
[PMID] 27746850.
2016
Projected Impact of Dengue Vaccination in Yucatán, Mexico.
PLoS neglected tropical diseases.
10(5)
[DOI] 10.1371/journal.pntd.0004661.
[PMID] 27227883.
2016
Quantifying the Epidemiological Impact of Vector Control on Dengue.
PLoS neglected tropical diseases.
10(5)
[DOI] 10.1371/journal.pntd.0004588.
[PMID] 27227829.
2016
Spatiotemporal dynamics of the Ebola epidemic in Guinea and implications for vaccination and disease elimination: a computational modeling analysis.
BMC medicine.
14(1)
[DOI] 10.1186/s12916-016-0678-3.
[PMID] 27600737.
2016
The epidemiology and transmissibility of Zika virus in Girardot and San Andres island, Colombia, September 2015 to January 2016.
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
21(28)
[DOI] 10.2807/1560-7917.ES.2016.21.28.30283.
[PMID] 27452806.
2016
The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.
PLoS medicine.
13(11)
[DOI] 10.1371/journal.pmed.1002181.
[PMID] 27898668.
2016
Transmissibility and Pathogenicity of Ebola Virus: A Systematic Review and Meta-analysis of Household Secondary Attack Rate and Asymptomatic Infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
62(10):1277-1286
[DOI] 10.1093/cid/ciw114.
[PMID] 26932131.
2016
Transmission dynamics of Ebola virus disease and intervention effectiveness in Sierra Leone.
Proceedings of the National Academy of Sciences of the United States of America.
113(16):4488-93
[DOI] 10.1073/pnas.1518587113.
[PMID] 27035948.
2015
Cholera Transmission in Ouest Department of Haiti: Dynamic Modeling and the Future of the Epidemic.
PLoS neglected tropical diseases.
9(10)
[DOI] 10.1371/journal.pntd.0004153.
[PMID] 26488620.
2015
Ebola vaccination – Authors’ reply.
Lancet (London, England).
386(10012)
[DOI] 10.1016/S0140-6736(15)00951-4.
[PMID] 26738716.
2015
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
Lancet (London, England).
386(9996):857-66
[DOI] 10.1016/S0140-6736(15)61117-5.
[PMID] 26248676.
2015
Household transmissibility of avian influenza A (H7N9) virus, China, February to May 2013 and October 2013 to March 2014.
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
20(10)
[PMID] 25788253.
2015
Increased isolation frequency of toxigenic Vibrio cholerae O1 from environmental monitoring sites in Haiti.
PloS one.
10(4)
[DOI] 10.1371/journal.pone.0124098.
[PMID] 25853552.
2015
One versus two doses: What is the best use of vaccine in an influenza pandemic?
Epidemics.
13:17-27
[DOI] 10.1016/j.epidem.2015.06.001.
[PMID] 26616038.
2015
Spatiotemporal spread of the 2014 outbreak of Ebola virus disease in Liberia and the effectiveness of non-pharmaceutical interventions: a computational modelling analysis.
The Lancet. Infectious diseases.
15(2):204-11
[DOI] 10.1016/S1473-3099(14)71074-6.
[PMID] 25575618.
2015
The contribution of neighbours to an individual’s risk of typhoid outcome.
Epidemiology and infection.
143(16):3520-7
[DOI] 10.1017/S0950268815000692.
[PMID] 25936682.
2015
The dengue vaccine pipeline: Implications for the future of dengue control.
Vaccine.
33(29):3293-8
[DOI] 10.1016/j.vaccine.2015.05.010.
[PMID] 25989449.
2015
Vaccine testing. Ebola and beyond.
Science (New York, N.Y.).
348(6230):46-8
[DOI] 10.1126/science.aaa3178.
[PMID] 25838371.
2014
Assessing the Impact of Travel Restrictions On International Spread of the 2014 West African Ebola Epidemic
Eurosurveillance.
19(42):8-13
2014
Assessing the impact of travel restrictions on international spread of the 2014 West African Ebola epidemic.
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
19(42)
[PMID] 25358040.
2014
Assessing the international spreading risk associated with the 2014 west african ebola outbreak.
PLoS currents.
6
[DOI] 10.1371/currents.outbreaks.cd818f63d40e24aef769dda7df9e0da5.
[PMID] 25642360.
2014
Comparative effectiveness of different strategies of oral cholera vaccination in bangladesh: a modeling study.
PLoS neglected tropical diseases.
8(12)
[DOI] 10.1371/journal.pntd.0003343.
[PMID] 25473851.
2014
Ebola: mobility data.
Science (New York, N.Y.).
346(6208)
[DOI] 10.1126/science.346.6208.433-a.
[PMID] 25342792.
2014
Emerging, evolving, and established infectious diseases and interventions.
Science (New York, N.Y.).
345(6202):1292-4
[DOI] 10.1126/science.1254166.
[PMID] 25214617.
2014
Genetic variation of Vibrio cholerae during outbreaks, Bangladesh, 2010-2011.
Emerging infectious diseases.
20(1):54-60
[DOI] 10.3201/eid2001.130796.
[PMID] 24377372.
2014
Household Transmission of Vibrio cholerae in Bangladesh.
PLoS neglected tropical diseases.
8(11)
[DOI] 10.1371/journal.pntd.0003314.
[PMID] 25411971.
2014
Modeling cholera outbreaks.
Current topics in microbiology and immunology.
379:195-209
[DOI] 10.1007/82_2013_307.
[PMID] 23412687.
2014
School-located influenza vaccination reduces community risk for influenza and influenza-like illness emergency care visits.
PloS one.
9(12)
[DOI] 10.1371/journal.pone.0114479.
[PMID] 25489850.
2013
Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?
AIDS (London, England).
27(6):981-989
[DOI] 10.1097/QAD.0b013e32835cb927.
[PMID] 23196933.
2013
Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?
AIDS (London, England).
27(15):2494-6
[DOI] 10.1097/01.aids.0000432463.23508.a2.
[PMID] 24029738.
2013
Optimal vaccine allocation for the early mitigation of pandemic influenza.
PLoS computational biology.
9(3)
[DOI] 10.1371/journal.pcbi.1002964.
[PMID] 23555207.
2013
The effects of vector movement and distribution in a mathematical model of dengue transmission.
PloS one.
8(10)
[DOI] 10.1371/journal.pone.0076044.
[PMID] 24204590.
2013
Understanding HIV epidemics: aggregate viral load metrics and ‘smoking guns’.
AIDS (London, England).
27(17):2826-7
[DOI] 10.1097/QAD.0000000000000002.
[PMID] 24384634.
2012
A hybrid EM and Monte Carlo EM algorithm and its application to analysis of transmission of infectious diseases.
Biometrics.
68(4):1238-49
[DOI] 10.1111/j.1541-0420.2012.01757.x.
[PMID] 22506893.
2012
A Mathematical Model for the Control of Dengue Using Vaccines
International Journal of Infectious Diseases.
16
[DOI] 10.1016/j.ijid.2012.05.985.
2012
A theoretic framework to consider the effect of immunizing schoolchildren against influenza: implications for research.
Pediatrics.
129 Suppl 2:S63-7
[DOI] 10.1542/peds.2011-0737D.
[PMID] 22383483.
2012
Assessing the potential of a candidate dengue vaccine with mathematical modeling.
PLoS neglected tropical diseases.
6(3)
[DOI] 10.1371/journal.pntd.0001450.
[PMID] 22479655.
2012
Controlling dengue with vaccines in Thailand.
PLoS neglected tropical diseases.
6(10)
[DOI] 10.1371/journal.pntd.0001876.
[PMID] 23145197.
2012
Critical immune and vaccination thresholds for determining multiple influenza epidemic waves.
Epidemics.
4(1):22-32
[DOI] 10.1016/j.epidem.2011.11.003.
[PMID] 22325011.
2012
ESTIMATING WITHIN-SCHOOL CONTACT NETWORKS TO UNDERSTAND INFLUENZA TRANSMISSION.
The annals of applied statistics.
6(1):1-26
[PMID] 22639701.
2012
The global spread of drug-resistant influenza.
Journal of the Royal Society, Interface.
9(69):648-56
[DOI] 10.1098/rsif.2011.0427.
[PMID] 21865253.
2011
ESTIMATING WITHIN-HOUSEHOLD CONTACT NETWORKS FROM EGOCENTRIC DATA.
The annals of applied statistics.
5(3):1816-1838
[PMID] 22427793.
2011
Hand, foot, and mouth disease in China: patterns of spread and transmissibility.
Epidemiology (Cambridge, Mass.).
22(6):781-92
[DOI] 10.1097/EDE.0b013e318231d67a.
[PMID] 21968769.
2011
Planning for the control of pandemic influenza A (H1N1) in Los Angeles County and the United States.
American journal of epidemiology.
173(10):1121-30
[DOI] 10.1093/aje/kwq497.
[PMID] 21427173.
2011
The effect of age on transmission of 2009 pandemic influenza A (H1N1) in a camp and associated households.
Epidemiology (Cambridge, Mass.).
22(2):180-7
[DOI] 10.1097/EDE.0b013e3182060ca5.
[PMID] 21233714.
2011
The global transmission and control of influenza.
PloS one.
6(5)
[DOI] 10.1371/journal.pone.0019515.
[PMID] 21573121.
2011
Vaccination strategies for epidemic cholera in Haiti with implications for the developing world.
Proceedings of the National Academy of Sciences of the United States of America.
108(17):7081-5
[DOI] 10.1073/pnas.1102149108.
[PMID] 21482756.
2010
El Tor cholera with severe disease: a new threat to Asia and beyond.
Epidemiology and infection.
138(3):347-52
[DOI] 10.1017/S0950268809990550.
[PMID] 19678971.
2010
FluTE, a publicly available stochastic influenza epidemic simulation model.
PLoS computational biology.
6(1)
[DOI] 10.1371/journal.pcbi.1000656.
[PMID] 20126529.
2010
Modeling Competing Infectious Pathogens from a Bayesian Perspective: Application to Influenza Studies with Incomplete Laboratory Results.
Journal of the American Statistical Association.
105(492):1310-1322
[PMID] 21472041.
2010
Optimizing vaccine allocation at different points in time during an epidemic.
PloS one.
5(11)
[DOI] 10.1371/journal.pone.0013767.
[PMID] 21085686.
2010
Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2.
Sexually transmitted diseases.
37(5):290-7
[DOI] 10.1097/OLQ.0b013e3181d3d023.
[PMID] 20351622.
2010
School opening dates predict pandemic influenza A(H1N1) outbreaks in the United States.
The Journal of infectious diseases.
202(6):877-80
[DOI] 10.1086/655810.
[PMID] 20704486.
2010
Studies needed to address public health challenges of the 2009 H1N1 influenza pandemic: insights from modeling.
PLoS medicine.
7(6)
[DOI] 10.1371/journal.pmed.1000275.
[PMID] 20532237.
2010
Towards a quantitative understanding of the within-host dynamics of influenza A infections.
Journal of the Royal Society, Interface.
7(42):35-47
[DOI] 10.1098/rsif.2009.0067.
[PMID] 19474085.
2009
A Bayesian model for evaluating influenza antiviral efficacy in household studies with asymptomatic infections.
Biostatistics (Oxford, England).
10(2):390-403
[DOI] 10.1093/biostatistics/kxn045.
[PMID] 19202152.
2009
A/H1N1 flu pandemic. Antiviral drugs: distinguish treatment from prophylaxis.
BMJ (Clinical research ed.).
339
[DOI] 10.1136/bmj.b3620.
[PMID] 19737833.
2009
Antiviral resistance and the control of pandemic influenza: the roles of stochasticity, evolution and model details.
Journal of theoretical biology.
256(1):117-25
[DOI] 10.1016/j.jtbi.2008.09.021.
[PMID] 18952105.
2009
Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
12(2):226-33
[DOI] 10.1111/j.1524-4733.2008.00437.x.
[PMID] 18671770.
2009
Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics.
Proceedings of the National Academy of Sciences of the United States of America.
106(33):13980-5
[DOI] 10.1073/pnas.0901720106.
[PMID] 19666590.
2009
Intervention strategies for an influenza pandemic taking into account secondary bacterial infections.
Epidemics.
1(3):185-95
[DOI] 10.1016/j.epidem.2009.09.001.
[PMID] 20161493.
2009
Public health. The cholera crisis in Africa.
Science (New York, N.Y.).
324(5929)
[DOI] 10.1126/science.1173890.
[PMID] 19443768.
2009
Quantitative assessment of the role of male circumcision in HIV epidemiology at the population level.
Epidemics.
1(3):139-52
[DOI] 10.1016/j.epidem.2009.08.001.
[PMID] 21352761.
2009
Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States.
American journal of epidemiology.
170(6):679-86
[DOI] 10.1093/aje/kwp237.
[PMID] 19679750.
2009
The transmissibility and control of pandemic influenza A (H1N1) virus.
Science (New York, N.Y.).
326(5953):729-33
[DOI] 10.1126/science.1177373.
[PMID] 19745114.
2008
A Bayesian Framework for Estimating Vaccine Efficacy per Infectious Contact.
The annals of applied statistics.
2(4):1409-1431
[PMID] 19169384.
2008
Estimating influenza vaccine efficacy from challenge and community-based study data.
American journal of epidemiology.
168(12):1343-52
[DOI] 10.1093/aje/kwn259.
[PMID] 18974084.
2008
Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa.
PloS one.
3(5)
[DOI] 10.1371/journal.pone.0002230.
[PMID] 18493617.
2008
Modeling targeted layered containment of an influenza pandemic in the United States.
Proceedings of the National Academy of Sciences of the United States of America.
105(12):4639-44
[DOI] 10.1073/pnas.0706849105.
[PMID] 18332436.
2008
No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa.
AIDS (London, England).
22(9):1055-61
[DOI] 10.1097/QAD.0b013e3282f8af84.
[PMID] 18520349.
2007
A Data-Augmentation Method for Infectious Disease Incidence Data from Close Contact Groups.
Computational statistics & data analysis.
51(12):6582-6595
[PMID] 18704156.
2007
A Resampling-Based Test to Detect Person-To-Person Transmission of Infectious Disease.
The annals of applied statistics.
1(1):211-228
[PMID] 19436773.
2007
Analytic insights into the population level impact of imperfect prophylactic HIV vaccines.
Journal of acquired immune deficiency syndromes (1999).
45(4):454-67
[PMID] 17554215.
2007
Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials.
American journal of epidemiology.
165(2):212-21
[PMID] 17088311.
2007
Containing a large bioterrorist smallpox attack: a computer simulation approach.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
11(2):98-108
[PMID] 16899385.
2007
Controlling endemic cholera with oral vaccines.
PLoS medicine.
4(11)
[PMID] 18044983.
2007
Detecting human-to-human transmission of avian influenza A (H5N1).
Emerging infectious diseases.
13(9):1348-53
[DOI] 10.3201/eid1309.070111.
[PMID] 18252106.
2007
Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004.
Vaccine.
25(20):4038-45
[PMID] 17395338.
2007
Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread.
PLoS computational biology.
3(12)
[PMID] 18069885.
2007
What is the best control strategy for multiple infectious disease outbreaks?
Proceedings. Biological sciences.
274(1611):833-7
[PMID] 17251095.
2006
Design and Evaluation of Prophylactic Interventions Using Infectious Disease Incidence Data from Close Contact Groups.
Journal of the Royal Statistical Society. Series C, Applied statistics.
55(3):317-330
[PMID] 22457545.
2006
Mitigation strategies for pandemic influenza in the United States.
Proceedings of the National Academy of Sciences of the United States of America.
103(15):5935-40
[PMID] 16585506.
2006
Public health. Community studies for vaccinating schoolchildren against influenza.
Science (New York, N.Y.).
311(5761):615-6
[PMID] 16456066.
2005
Containing pandemic influenza at the source.
Science (New York, N.Y.).
309(5737):1083-7
[PMID] 16079251.
2005
Critical factors influencing the occurrence of Vibrio cholerae in the environment of Bangladesh.
Applied and environmental microbiology.
71(8):4645-54
[PMID] 16085859.
2005
Finding optimal vaccination strategies for pandemic influenza using genetic algorithms.
Journal of theoretical biology.
234(2):201-12
[PMID] 15757679.
2005
Population-wide benefits of routine vaccination of children against influenza.
Vaccine.
23(10):1284-93
[PMID] 15652671.
2005
Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.
PLoS medicine.
2(8)
[PMID] 16018721.
2005
Strategy for distribution of influenza vaccine to high-risk groups and children.
American journal of epidemiology.
161(4):303-6
[PMID] 15692073.
2004
Containing pandemic influenza with antiviral agents.
American journal of epidemiology.
159(7):623-33
[PMID] 15033640.
2004
Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children.
Archives of pediatrics & adolescent medicine.
158(1):65-73
[PMID] 14706961.
2004
Safety of cold-adapted live influenza vaccine.
The Pediatric infectious disease journal.
23(6):593-4; author reply 594
[PMID] 15194854.
2003
A 4-year study of the epidemiology of Vibrio cholerae in four rural areas of Bangladesh.
The Journal of infectious diseases.
187(1):96-101
[PMID] 12508151.
2003
Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures.
American journal of epidemiology.
158(4):305-11
[PMID] 12915495.
2002
Community interventions and the epidemic prevention potential.
Vaccine.
20(27-28):3254-62
[PMID] 12213394.
2002
Epidemic and endemic cholera trends over a 33-year period in Bangladesh.
The Journal of infectious diseases.
186(2):246-51
[PMID] 12134262.
2002
Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand.
American journal of epidemiology.
155(2):159-68
[PMID] 11790680.
2001
Nonparametric maximum likelihood estimation for competing risks survival data subject to interval censoring and truncation.
Biometrics.
57(1):74-80
[PMID] 11252621.
2000
Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control.
Vaccine.
18(18):1902-9
[PMID] 10699339.
2000
Modeling markers of disease progression by a hidden Markov process: application to characterizing CD4 cell decline.
Biometrics.
56(3):733-41
[PMID] 10985209.
1999
A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines.
Statistics in medicine.
18(1):53-68
[PMID] 9990692.
1999
Design and interpretation of vaccine field studies.
Epidemiologic reviews.
21(1):73-88
[PMID] 10520474.
1999
Efficiency of estimating vaccine efficacy for susceptibility and infectiousness: randomization by individual versus household.
Biometrics.
55(3):792-8
[PMID] 11315008.
1999
Semiparametric methods for multiple exposure mismeasurement and a bivariate outcome in HIV vaccine trials.
Biometrics.
55(1):94-101
[PMID] 11318183.
1998
Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy.
Statistics in medicine.
17(2):185-200
[PMID] 9483728.
1998
Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines.
American journal of epidemiology.
147(10):948-59
[PMID] 9596473.
1998
Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations.
Statistics in medicine.
17(10):1121-36
[PMID] 9618773.
1998
Semi-parametric models for mismeasured exposure information in vaccine trials.
Statistics in medicine.
17(20):2335-52
[PMID] 9819831.
1997
Study designs for evaluating different efficacy and effectiveness aspects of vaccines.
American journal of epidemiology.
146(10):789-803
[PMID] 9384199.
1996
Estimability and interpretation of vaccine efficacy using frailty mixing models.
American journal of epidemiology.
144(1):83-97
[PMID] 8659489.
1996
Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
13(5):440-7
[PMID] 8970471.
1996
Use of immunological markers and continuous-time Markov models to estimate progression of HIV infection in homosexual men.
AIDS (London, England).
10(6):649-56
[PMID] 8780820.
1995
AIDS: modeling epidemic control.
Science (New York, N.Y.).
267(5202):1250-1; author reply 1252
[PMID] 7871414.
1995
The effect of disease prior to an outbreak on estimates of vaccine efficacy following the outbreak.
American journal of epidemiology.
141(10):980-90
[PMID] 7741128.
1994
Estimation of incidence of HIV infection using cross-sectional marker surveys.
Biometrics.
50(3):675-88
[PMID] 7981394.
1994
Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field.
Statistics in medicine.
13(4):357-77
[PMID] 8177986.
1994
Modelling the female-to-male per-act HIV transmission probability in an emerging epidemic in Asia.
Statistics in medicine.
13(19-20):2097-106
[PMID] 7846413.
1994
Probability of female-to-male transmission of HIV-1 in Thailand.
Lancet (London, England).
343(8891):204-7
[PMID] 7904668.
1994
Role of the primary infection in epidemics of HIV infection in gay cohorts.
Journal of acquired immune deficiency syndromes.
7(11):1169-84
[PMID] 7932084.
1994
The ecological effects of individual exposures and nonlinear disease dynamics in populations.
American journal of public health.
84(5):836-42
[PMID] 8179058.
1993
Effect of routine use of therapy in slowing the clinical course of human immunodeficiency virus (HIV) infection in a population-based cohort.
American journal of epidemiology.
137(11):1229-40
[PMID] 8100682.
1993
Estimates of the US health impact of influenza.
American journal of public health.
83(12):1712-6
[PMID] 8259800.
1993
Estimation of vaccine efficacy from epidemics of acute infectious agents under vaccine-related heterogeneity.
Mathematical biosciences.
117(1-2):271-81
[PMID] 8400580.
1993
Measuring vaccine efficacy from epidemics of acute infectious agents.
Statistics in medicine.
12(3-4):249-63
[PMID] 8456210.
1992
A discrete-time model for the statistical analysis of infectious disease incidence data.
Biometrics.
48(1):117-28
[PMID] 1316178.
1992
Estimating the stage-specific numbers of HIV infection using a Markov model and back-calculation.
Statistics in medicine.
11(6):831-43
[PMID] 1594820.
1992
Interpretation and estimation of vaccine efficacy under heterogeneity.
American journal of epidemiology.
136(3):328-43
[PMID] 1415152.
1991
A generalized stochastic model for the analysis of infectious disease final size data.
Biometrics.
47(3):961-74
[PMID] 1742449.
1991
A simulation model of AIDS in San Francisco: I. Model formulation and parameter estimation.
Mathematical biosciences.
106(2):203-22
[PMID] 1806102.
1991
Assessing risk factors for transmission of infection.
American journal of epidemiology.
133(12):1199-209
[PMID] 2063828.
1991
Determinants and predictors of dengue infection in Mexico.
American journal of epidemiology.
133(11):1168-78
[PMID] 2035520.
1991
Direct and indirect effects in vaccine efficacy and effectiveness.
American journal of epidemiology.
133(4):323-31
[PMID] 1899778.
1991
Estimation of vaccine efficacy in outbreaks of acute infectious diseases.
Statistics in medicine.
10(10):1573-84
[PMID] 1947513.
1991
Measures of the effects of vaccination in a randomly mixing population.
International journal of epidemiology.
20(1):300-10
[PMID] 2066239.
1991
The dynamics of CD4+ T-lymphocyte decline in HIV-infected individuals: a Markov modeling approach.
Journal of acquired immune deficiency syndromes.
4(11):1141-7
[PMID] 1684387.
1990
[Direct and indirect effects of vaccines: an annotation on the estimation of the vaccine efficacy from outbreaks caused by acute infection agents such as measles].
Boletin medico del Hospital Infantil de Mexico.
47(7):516-9
[PMID] 2206419.
1990
Estimating benefits of screening from observational cohort studies.
Statistics in medicine.
9(8):969-80
[PMID] 2218198.
1990
Modeling the decline of CD4+ T-lymphocyte counts in HIV-infected individuals.
Journal of acquired immune deficiency syndromes.
3(9):930-1
[PMID] 1974629.
1990
Simulation of mechanisms of viral interference in influenza.
International journal of epidemiology.
19(2):444-54
[PMID] 2376460.
1989
Duration of human immunodeficiency virus infection before detection of antibody.
Lancet (London, England).
2(8664):637-40
[PMID] 2570898.
1989
Re: “Use of Modeling in Infectious Disease Epidemiology”.
American journal of epidemiology.
130(3):619-21
[PMID] 2764009.
1989
Statistical analysis of the stages of HIV infection using a Markov model.
Statistics in medicine.
8(7):831-43
[PMID] 2772443.
1989
The Tecumseh Study. XVI: Family and community sources of rotavirus infection.
American journal of epidemiology.
130(4):760-8
[PMID] 2773919.
1988
Efficacy of virucidal nasal tissues in interrupting familial transmission of respiratory agents. A field trial in Tecumseh, Michigan.
American journal of epidemiology.
128(3):639-44
[PMID] 2843040.
1988
Models for the statistical analysis of infectious disease data.
Biometrics.
44(1):163-73
[PMID] 3358986.
1988
Statistical inference for infectious diseases. Risk-specific household and community transmission parameters.
American journal of epidemiology.
128(4):845-59
[PMID] 3421247.
1986
Predicting the global spread of new infectious agents.
American journal of epidemiology.
123(3):383-91
[PMID] 3946385.
1985
Tecumseh study of illness. XIII. Influenza infection and disease, 1976-1981.
American journal of epidemiology.
121(6):811-22
[PMID] 4014174.
1984
Environmental and genetic sources of familial aggregation of blood pressure in Tecumseh, Michigan.
American journal of epidemiology.
120(1):131-44
[PMID] 6741914.
1984
Genetic and environmental sources of familial aggregation of body mass in Tecumseh, Michigan.
Human biology.
56(4):733-57
[PMID] 6530223.
1984
Simulation studies of influenza epidemics: assessment of parameter estimation and sensitivity.
International journal of epidemiology.
13(4):496-501
[PMID] 6519891.
1984
Statistical procedures for estimating the community probability of illness in family studies: rhinovirus and influenza.
International journal of epidemiology.
13(1):99-106
[PMID] 6321368.
1984
The Tecumseh Community Health Study.
Progress in clinical and biological research.
147:43-5
[PMID] 6739493.
1983
[Procedures for estimating transmission parameters from influenza epidemics: use of serological data].
Voprosy virusologii.
(2):176-82
[PMID] 6868556.
1983
Models of epidemics and endemicity in genetically variable host populations.
Journal of mathematical biology.
17(3):289-304
[PMID] 6619663.
1983
The Tecumseh study. XII. Enteric agents in the community, 1976-1981.
The Journal of infectious diseases.
148(2):284-91
[PMID] 6310002.
1982
Estimating household and community transmission parameters for influenza.
American journal of epidemiology.
115(5):736-51
[PMID] 7081204.
1982
Household and community transmission parameters from final distributions of infections in households.
Biometrics.
38(1):115-26
[PMID] 7082755.
Considerations for the design of vaccine efficacy trials during public health emergencies
.
[DOI] 10.1101/261875.
Cryptic transmission of SARS-CoV-2 and the first COVID-19 wave in Europe and the United States
.
[DOI] 10.1101/2021.03.24.21254199.
[PMID] 33791745.
Effectiveness of SARS-CoV-2 Vaccines against Omicron Infection and Severe Events: A Systematic Review and Meta-Analysis of Test-Negative Design Studies
.
[DOI] 10.1101/2023.02.16.23286041.
Estimating the establishment of local transmission and the cryptic phase of the COVID-19 pandemic in the USA
.
[DOI] 10.1101/2020.07.06.20140285.
[PMID] 32676609.
Evaluating targeted COVID-19 vaccination strategies with agent-based modeling
.
[DOI] 10.1101/2023.03.09.23285319.
[PMID] 36945423.
Guiding Vaccine Efficacy Trial Design During Public Health Emergencies: An interactive web-based decision support tool
.
[DOI] 10.1101/252783.
Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate
.
[DOI] 10.1101/2020.07.29.20164590.
[PMID] 32766596.
Modeling the impact of social distancing, testing, contact tracing and household quarantine on second-wave scenarios of the COVID-19 epidemic
.
[DOI] 10.1101/2020.05.06.20092841.
[PMID] 32511536.
Quantifying the importance and location of SARS-CoV-2 transmission events in large metropolitan areas
.
[DOI] 10.1101/2020.12.15.20248273.
Simulations for Designing and Interpreting Intervention Trials in Infectious Diseases
.
[DOI] 10.1101/198051.
Updated projections for COVID-19 omicron wave in Florida
.
[DOI] 10.1101/2022.01.06.22268849.
[PMID] 35018391.
Using simulated infectious disease outbreaks to guide the design of individually randomized vaccine trials
.
[DOI] 10.1101/2021.01.29.21250703.
Grants
Jan 2023
– May 2023
Covid 19 (cont) 2022/1314190-0_PO 203037053: Re: Continued work on clinical trial designs, statistical analysis and clinical evaluation of candidate vaccines and therapeutics to be used during Public Health Emergencies current ongoing COVID-19 pandemic
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Sep 2022
ACTIVE
Building mathematical modeling workforce capacity to support infectious disease and healthcare research
Role: Co-Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2022
ACTIVE
Developing TranStat: A user-friendly R package for the analysis of infectious disease transmission and control among close contacts
Role: Principal Investigator
Funding: UNIVERSITY OF GEORGIA
via NATL INST OF HLTH NIAID
Jan 2022
– Dec 2022
2022 WHO Contract_PI: Longini
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Aug 2021
ACTIVE
Design and Analysis of Vaccine Trials for Emerging Infectious Disease Threats
Role: Principal Investigator
Funding: EMORY UNIV
via NATL INST OF HLTH NIAID
Aug 2021
ACTIVE
Targeted vaccination strategies for COVID-19: A mathematical modeling approach UFF F020981
Role: Principal Investigator
Funding: UF FOUNDATION
via GOLDMAN SACHS PHILANTHROPY FUND
Jun 2021
– May 2023
Targeted vaccination strategies for COVID-19: A mathematical modeling approach
Role: Principal Investigator
Funding: SCHWAB CHARITABLE
via CONWAY FAMILY FOUNDATION
Jan 2021
– Dec 2021
2021 WHO Contract_PI: Longini
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Sep 2020
– Aug 2022
Mathematical and Statistical Methods for the Control of Global Infectious Disease Threats
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
May 2020
– Dec 2020
WHO FY21/ PI: Longini
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Apr 2020
ACTIVE
Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases
Role: Principal Investigator
Funding: EMORY UNIV
via NATL INST OF HLTH NIAID
Jan 2020
– Apr 2020
WHO 2020
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Jun 2019
– Dec 2019
WHO 2019 Agreement_PI: Longini
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Jun 2019
– May 2020
Yr.6 Methods of Evaluating Vaccine Efficacy
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIAID
Aug 2018
– Jul 2021
Design and Analysis of Vaccine Trials for Emerging Infectious Disease Threats
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Jul 2018
– Jun 2019
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Research Project 1 – Modeling, Spacial, Statistics
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2018
– Jun 2019
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Research Project 3 – Understanding Transmission with Integrated Genetic and Epidemiologic Inference
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2018
– Jun 2019
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Software Development and Core Facilities
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jun 2018
– May 2019
Yr.5 Methods of Evaluating Vaccine Efficacy
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIAID
Jan 2018
– Dec 2018
WHO 2018 Agreement_PI: Longini
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Jan 2018
– Dec 2020
Regression, Phylogenetics, and Study Design in Infectious Disease Epidemiology
Role: Co-Investigator
Funding: OHIO STATE UNIV
via NATL INST OF HLTH NIAID
Aug 2017
– May 2018
Methods for Evaluating Vaccine Efficacy Supplement
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIAID
Jul 2017
– Jun 2018
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Research Project 1 – Modeling, Spacial, Statistics
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2017
– Jun 2018
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Research Project 3 – Understanding Transmission with Integrated Genetic and Epidemiologic Inference
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2017
– Jun 2018
CSQUID U54- Software Development_Yr.4
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2017
– Sep 2017
To provide technical support to the WHO Blueprint and develop a guidance document for vaccine clinical evaluation in Public Health Emergencies
Role: Other
Funding: WORLD HLTH ORGANIZATION
Jun 2017
– May 2018
Methods of Evaluating Vaccine Efficacy_Yr.4
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIAID
May 2017
– Aug 2018
Targeted Vaccination of Children in Urban Slums against Cholera: Evaluation of Potentially Cost effective and Impactful Strategy for Deploying Oral Cholera Vaccine against Endemic Cholera in Bangladesh
Role: Principal Investigator
Funding: INTL CENTRE FOR DIARRHOEAL DISEASE RES
Apr 2017
– Dec 2017
WHO agreement_PI: Longini
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Jan 2017
– Dec 2021
Dynamics of Influenza Transmission in Nicaraguan Households
Role: Principal Investigator
Funding: UNIV OF MICHIGAN
via NATL INST OF HLTH NIAID
Aug 2016
– Jan 2017
Dengue Vaccine Seroprevalence Surveys
Role: Other
Funding: WORLD HLTH ORGANIZATION
Aug 2016
– Feb 2021
Aspen Award for Scientific Research & Collaboration between Italy and the United States
Role: Principal Investigator
Funding: MISCELLANEOUS DONORS
Jul 2016
– Jun 2017
Center for statistics and quantitative infectious disease (csquid): software development and core facilities
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH
Jul 2016
– Jun 2017
center for statistics and quantitative infectious diseases (csquid): policy studies
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2016
– Jun 2017
center for statistics and quantitative infectious diseases (csquid): project 1 modeling , special, statistics
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2016
– Jun 2017
center for statistics and quantitative infectious diseases (csquid): research project 3 understanding transmission
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2016
– Jun 2017
Zika Study- Center for Statistics and Quantitative Infectious Disease
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH
May 2016
– Apr 2017
Harnessing spatial heterogeneity to contain Zika virus transmission
Role: Principal Investigator
Funding: EMORY UNIV
via NATL SCIENCE FOU
Oct 2015
– Aug 2016
Statistical analysis of the Ebola ring vaccine trial in Guinea
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Jul 2015
– Jun 2016
Center for Statistics and Quantitative Infectious Diseases
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2015
– Jun 2016
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Policy Studies
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2015
– Jun 2016
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Research Project 3 – Understanding Transmission with Integrated Genetic and Epidemiologic Inference
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2015
– Jun 2016
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Software Development and Core Facilities
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2015
– Jun 2016
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Training, Outreach, and Diversity Plans
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jun 2015
– May 2018
Spatio-Temporal Modeling for Surveillance Data of Multiple Pathogens
Role: Project Manager
Funding: NATL INST OF HLTH NIAID
Jun 2015
– May 2017
Methods for evaluating vaccine efficacy
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH
May 2014
– Aug 2016
Dengue baseline studies and vaccine efficacy field trials in Yucat?n, Mexico
Role: Principal Investigator
Funding: Universidad Autonoma de Yucatan
via SANOFI
Feb 2014
– Jan 2019
Quantifying the balance between vaccine-induced T cell protection and pathology
Role: Principal Investigator
Funding: EMORY UNIV
via NATL INST OF HLTH NIAID
Apr 2013
– Sep 2016
Dengue Vaccine Initiative
Role: Principal Investigator
Funding: INTERNATIONAL VACCINE INSTITUTE
Dec 2011
– Jun 2016
Cholera Transmission in Gressier Region, Haiti
Role: Project Manager
Funding: NATL INST OF HLTH NIAID
Jun 2010
– May 2017
Epidemiology and Ecology of Vibrio cholerae in Bangladesh
Role: Project Manager
Funding: JOHNS HOPKINS UNIVERSITY
via NATL INST OF HLTH
Contact Details
Phones:
- Business:
- (352) 294-1938
Emails:
- Business:
- ilongini@ufl.edu
Addresses:
- Business Mailing:
-
P O BOX 117450
P O BOX 117450
22 BUCKMAN DRIVE, 452 DAUER HALL
GAINESVILLE FL 326110001 - Business Street:
-
228 BUCKMAN DR 452
DAUER HALL
GAINESVILLE FL 32611